These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33991177)

  • 1. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
    Carli ALE; Afshar-Sterle S; Rai A; Fang H; O'Keefe R; Tse J; Ferguson FM; Gray NS; Ernst M; Greening DW; Buchert M
    Proteomics; 2021 Jul; 21(13-14):e2000098. PubMed ID: 33991177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCLK1 induces a pro-tumorigenic phenotype to drive gastric cancer progression.
    Afshar-Sterle S; Carli ALE; O'Keefe R; Tse J; Fischer S; Azimpour AI; Baloyan D; Elias L; Thilakasiri P; Patel O; Ferguson FM; Eissmann MF; Chand AL; Gray NS; Busuttil R; Boussioutas A; Lucet IS; Ernst M; Buchert M
    Sci Signal; 2024 Sep; 17(854):eabq4888. PubMed ID: 39288218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.
    Liu J; Feng Y; Zeng X; He M; Gong Y; Liu Y
    J Cell Mol Med; 2021 Feb; 25(4):1911-1926. PubMed ID: 33350586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
    Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
    Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
    Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
    Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axis.
    Liu ZQ; He WF; Wu YJ; Zhao SL; Wang L; Ouyang YY; Tang SY
    BMC Gastroenterol; 2020 May; 20(1):156. PubMed ID: 32423385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
    Wu X; Ruan Y; Jiang H; Xu C
    Int J Biochem Cell Biol; 2017 Apr; 85():66-74. PubMed ID: 28161486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.
    Liu H; Wen T; Zhou Y; Fan X; Du T; Gao T; Li L; Liu J; Yang L; Yao J; Ge Y; An G
    Biomed Res Int; 2019; 2019():1061979. PubMed ID: 31223610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
    Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
    PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
    Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
    Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
    Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
    Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
    Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
    Gao T; Wang M; Xu L; Wen T; Liu J; An G
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
    Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
    Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
    Wang J; Wang S; Zhou J; Qian Q
    Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.